Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27543447 | 0.87 | ALDH1A1 (0.51) | SCDCCNE1CDK2CDK5ALDH1A1 | |
| SCHEMBL5026015 | 0.80 | CCNE1 (0.44) | SCDCCNE1CDK2CDK5ALDH1A1 | |
| SCHEMBL5025190 | 0.78 | SMN1; SMN2 (0.42) | CCNE1CDK2CDK5ALDH1A1TSHR | |
| SCHEMBL5046778 | 0.78 | CCNE1 (0.45) | SCDCCNE1CDK2CDK5ALDH1A1 | |
| SCHEMBL5029591 | 0.78 | KCNJ5 (0.47) | CCNE1CDK2CDK5ALDH1A1LMNA | |
| SCHEMBL5027736 | 0.78 | AURKA (0.49) | CCNE1CDK2CDK5LMNANPC1 | |
| SCHEMBL6335118 | 0.78 | MAPK13 (0.56) | SCDCCNE1CDK2CDK5ALDH1A1 | |
| SCHEMBL5045081 | 0.77 | CCNE1 (0.42) | CCNE1CDK2CDK5ALDH1A1TP53 | |
| SCHEMBL5027769 | 0.76 | TSHR (0.45) | CCNE1CDK2CDK5TSHRLMNA | |
| SCHEMBL13467941 | 0.75 | CCNE1 (0.56) | CCNE1CDK2CDK5ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| EP-1299381-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2002000649-A9 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | SCD 4699/4885CCNE1 1042/4885CDK2 138/4885 |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | SCD 4655/4885CCNE1 199/4885CDK2 47/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | SCD 4180/4885CCNE1 106/4885CDK2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.